Skip to main content

Table 1 Trials of radiotherapy following local excision for DCIS

From: Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials

Trial NSABP-17 EORTC10853 UKCCCR SWE-DCIS
Characteristic     
Date 1985–1990 1986–1996 1990–1998 1987–1999
Patients Randomised 818 1010 1030 1046
Median follow-up 12 YEARS 4 YEARS 4.3 YEARS 5.2 YEARS
Symptomatic 19% 28% NA 12.9%
Central path review 76% 85% 79% 20%
Dose 50 Gy/25 Fraction 50 Gy/25 Fractions 50 Gy/25 Fractions 50 – 54 Gy/25–27 fractions
Quality by Jadad 4 4 4 4
Population Pre- and post-menopausal Pts. All pts had tumour free margins after BCT. Women with localized ductal carcinoma in situ detected by physical examination or mammography were eligible, both ductal carcinoma in situ and lobular carcinoma in situ were also eligible.
RT 411 pts
BCT403 pts
DCIS<5 cm 1 002/1 010 pts analysed Extent of free margins was not specified, evidence of invasive carcinoma or Paget's disease of the nipple, were ineligible for the study.
RT 502 pts
BCT 500 pts
Screening detected tumor, complete excision of the carcinoma, free margins. typical ductal hiperplasia excluded. Excluded patients with lobular carcinoma in situ or atypical ductal hyperplasia in the absence of ductal carcinoma in situ, those in whom pathological margins of disease were uncertain, and people with Paget's disease of the nipple.
RT 267
BCT 544
Pathology margins clear, DCIS grade I and II B/2 mm were classified as atypical ductal hyperplasia Exclusion criteria were Paget's disease of the nipple, invasive carcinoma or intracystic carcinoma in situ, ongoing pregnancy or a history of previous or concurrent malignancy
RT 534
BCT 533
  1. RT = radiotherapy; BCT = breast conserving treatment; DCIS = ductal carcinoma in situ